Clinical trial
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem…
NCT00421174 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00421174 |
|---|---|
| Title | Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) |
| Official title | A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Idiopathic Pneumonia Syndrome Following Allogeneic Cell Transplantation (BMTCTN0403) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Collaborators | Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) NIH National Marrow Donor Program |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumonia, Idiopathic Pneumonia Syndrome |
| Intervention type | Drug |
| Interventions | Etanercept, Placebo plus corticosteroid |
| Enrollment | 37 |
| Start date | Aug 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Jul 1, 2013 |
| First posted | Jan 11, 2007 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: